Showing results (161-170 of 184) with videos related to
Sort By:
Pageof 19
Gut|June 10, 2020
Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panelShahida Din, Alexandra Kent, Richard C Pollok, et al.Nature Genetics|April 29, 2008
Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's diseaseSheila A Fisher, Mark Tremelling, Carl A Anderson, et al.The Lancet. Gastroenterology & Hepatology|June 15, 2026
HLA-DRB1*01:03 in patients with inflammatory bowel disease: a genotype-phenotype association studyQian Zhang, Eathar Shakweh, Mohmmed Tauseef Sharip, et al.Journal of Crohn'S & Colitis|November 9, 2023
Antibody Responses to Influenza Vaccination are Diminished in Patients With Inflammatory Bowel Disease on Infliximab or TofacitinibZhigang Liu, James L Alexander, Kai Yee Eng, et al.Nature Communications|March 17, 2022
Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumabSimeng Lin, Nicholas A Kennedy, Aamir Saifuddin, et al.Gut|January 19, 2026
Associations between demographic, clinical and dietary factors and flares in inflammatory bowel disease: the PRognostic effect of Environmental factors in Crohn's and Colitis (PREdiCCt) prospective cohort studyNathan Constantine-Cooke, Beatriz Gros, Nikolas Plevris, et al.The Lancet. Gastroenterology & Hepatology|September 11, 2022
COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control studyJames L Alexander, Zhigang Liu, Diana Muñoz Sandoval, et al.Gut|April 19, 2020
British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemicNicholas A Kennedy, Gareth-Rhys Jones, Christopher A Lamb, et al.Eclinicalmedicine|October 16, 2023
Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort studyZhigang Liu, James L Alexander, Kaixing Le, et al.Journal of Crohn'S & Colitis|June 10, 2025
The effectiveness of second- and-third-line biologics in perianal Crohn's disease-a multicenter propensity score-matched studyUria Shani, Monica State, Radu Bogdan Mateescu, et al.Pageof 19